The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramos, O. F.
Right arrow Articles by Klein, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramos, O. F.
Right arrow Articles by Klein, E.

The Journal of Immunology, Vol 140, Issue 4 1239-1243, Copyright © 1988 by American Association of Immunologists

ARTICLES

The elevated natural killer sensitivity of targets carrying surface- attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors

OF Ramos, C Kai, E Yefenof and E Klein
Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden.

Human serum-treated Raji and Daudi cells were shown to bind C3 fragments on their surface as a consequence of their capacity to activate C via the alternative pathway. C3 molecules were detectable on the cell surfaces up to 24 h after serum exposure. The C3 fragment- coated cells showed increased sensitivity to spontaneous lymphocyte- mediated cytotoxicity. The effector lymphocytes involved in the enhanced cytotoxicity were NK cells with low buoyant density, carrying both CR3 and FcR. Blocking of the FcR and CR3 with F(ab)2 fragments from Leu-11c or Leu-15 mAb, respectively, did not influence the lysis of targets that did not carry C3 fragments. In contrast, the accessibility of CR3 on the effector lymphocytes was essential for the C3 fragment-mediated enhancement of cytotoxicity. In addition to the Leu-15 antibody, N-acetyl-D-Glucosamine, a compound known to block iC3b binding to CR3, also abrogated the C3 fragment-imposed effect. Our previous experiments showed that the C3 fragments bind to acceptor sites on target cells. The present experiments show that the C3 fragments fixed onto the target bind to CR3 on effector cells. These data substantiate the hypothesis that the bivalent C3 fragments, which are fixed on the targets, promote their interaction with lytic lymphocytes by bridging the two cells.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
R. Ohta, N. Kondor, N. Dohi, S. Tomlinson, M. Imai, V. M. Holers, H. Okada, and N. Okada
Mouse Complement Receptor-Related Gene y/p65-Neutralized Tumor Vaccine Induces Antitumor Activity In Vivo
J. Immunol., July 1, 2004; 173(1): 205 - 213.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. A. Caragine, M. Imai, A. B. Frey, and S. Tomlinson
Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell-mediated cytotoxicity
Blood, October 16, 2002; 100(9): 3304 - 3310.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
T. CHAVAKIS, S. M. KANSE, R. A. PIXLEY, A. E. MAY, I. ISORDIA-SALAS, R. W. COLMAN, and K. T. PREISSNER
Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen
FASEB J, November 1, 2001; 15(13): 2365 - 2376.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Sheng, M. B. Fairbanks, R. L. Heinrikson, G. Canziani, I. M. Chaiken, D. M. Mosser, H. Zhang, and R. W. Colman
Cleaved high molecular weight kininogen binds directly to the integrin CD11b/CD18 (Mac-1) and blocks adhesion to fibrinogen and ICAM-1
Blood, June 15, 2000; 95(12): 3788 - 3795.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.